Viking Therapeutics, Inc. Earnings

Viking Therapeutics, Inc.’s revenue jumped NaN% since last year same period to $0Mn in the Q3 2025. On a quarterly growth basis, Viking Therapeutics, Inc. has generated NaN% jump in its revenue since last 3-months.

Viking Therapeutics, Inc.’s net profit fell -264.02% since last year same period to $-90.79Mn in the Q3 2025. On a quarterly growth basis, Viking Therapeutics, Inc. has generated -38.48% fall in its net profits since last 3-months.

Viking Therapeutics, Inc.’s net profit margin jumped NaN% since last year same period to -Inf% in the Q3 2025. On a quarterly growth basis, Viking Therapeutics, Inc. has generated NaN% jump in its net profit margins since last 3-months.

Viking Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.92 - a -2.78% fall from last quarter’s estimates.

Viking Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at -0.92.

Viking Therapeutics, Inc.’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q1 2026. This indicates that the Viking Therapeutics, Inc. has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.